| Autor: |
Gallop K; Acaster Lloyd Consulting Ltd, London, United Kingdom., Hall R; Acaster Lloyd Consulting Ltd, London, United Kingdom., Watt M; AstraZeneca UK Ltd., London, United Kingdom., Squirrell D; AstraZeneca UK Ltd., London, United Kingdom., Branscombe N; AstraZeneca UK Ltd., Cambridge, United Kingdom., Arnetop S; AstraZeneca Ltd. Gothenburg, Sweden., Lloyd A; Acaster Lloyd Consulting Ltd, London, United Kingdom. |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of health economics and outcomes research [J Health Econ Outcomes Res] 2024 Jul 24; Vol. 11 (2), pp. 20-28. Date of Electronic Publication: 2024 Jul 24 (Print Publication: 2024). |
| DOI: |
10.36469/001c.120605 |
| Abstrakt: |
Background: Pre-exposure prophylaxis (PrEP) for COVID-19 provides additional protection, beyond vaccines alone, for individuals who are immunocompromised (IC). This may reduce the need for preventative behavioral modification, such as shielding-a behavioral restriction limiting an IC individual to minimize face-to-face interactions and/or crowded places. Therefore, PrEP may improve psychosocial well-being and health-related quality of life (HRQoL) for individuals with IC conditions. Objective: To estimate the potential HRQoL and utility benefit of PrEP for prevention of COVID-19 in individuals with IC conditions who may not have an adequate response of full vaccination (and therefore are at "highest risk" of severe COVID-19) that can be used in future economic evaluations of preventative therapies against COVID-19. Methods: Vignettes describing HRQoL associated with 2 pre-PrEP states (shielding and semi-shielding behavioral restrictions) and a post-PrEP state were developed from a literature review and tested through interviews with clinicians (n = 4) and individuals with IC conditions (n = 10). Vignettes were valued by a general population sample (N = 100) using a visual analog scale (VAS), time trade-off (TTO), and EQ-5D-5L. A sample of individuals with IC conditions (n = 48) valued their current HRQoL and a post-PrEP vignette using VAS and EQ-5D-5L. Results: Individuals with IC conditions reported a mean current EQ-5D-5L score of 0.574, and 0.656 for post-PrEP based on the vignette. PrEP would lead to behavior changes for 75% (30/40) of individuals with IC conditions and an emotional benefit for 93% (37/40) of individuals with IC conditions. Mean values from the general population valuation based on EQ-5D-5L ranged from 0.606 ("shielding") to 0.932 ("post-PrEP"). Conclusion: This study quantified the expected health state utility benefit of reduced psychosocial burden and behavioral restriction. PrEP would potentially result in a utility gain between 0.082 and 0.326, dependent on valuation approach and expected change in behavioral restrictions, leading to improvements in daily activities and emotional well-being. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
